I noticed that Pfizer has a presentation detailing an phase I trial using PF- 02341066 [oral c-met and ALK inhibitor] at ESMO next month. It's being presented in the "Presidential, Best Of 2009" group. Bipar's BSI-201 [PARP1] inhibitor is in the same group.
Market Data 
Markets 
AI
